In the last recent years, the introduction in the clinical setting of treatment combinations having immune checkpoint inhibitors as the backbone has dramatically improved the outcomes of patients suffering from advanced/metastatic renal cell carcinoma (RCC). Here we report the clinical course of a patient with a rapid and bulky bone recurrence of RCC after nephrectomy, experiencing long-term benefit from nivolumab-ipilimumab administered as first-line treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510992 | PMC |
| http://dx.doi.org/10.23750/abm.v93iS1.12876 | DOI Listing |
Publication Analysis
Top Keywords
renal cell
8
cell carcinoma
8
nivolumab-ipilimumab renal
4
carcinoma metastatic
4
metastatic bones
4
bones case
4
case report
4
report years
4
years introduction
4
introduction clinical
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!